In March 2025, the European market showed signs of resilience as the pan-European STOXX Europe 600 Index ended higher, buoyed by hopes of increased government spending despite ongoing concerns over impending U.S. tariffs. As central banks navigate a complex landscape marked by inflation worries and trade uncertainties, small-cap stocks in Europe present intriguing opportunities for investors seeking growth potential amid these broader economic dynamics.
Top 10 Undervalued Small Caps With Insider Buying In Europe
Overview: Sirius Real Estate is a property investment company focused on owning and operating business parks in Germany, with a market cap of approximately £1.25 billion.
Operations: The company's revenue primarily stems from property investment, with the latest reported revenue at €306.60 million. Cost of goods sold (COGS) was €128.3 million, resulting in a gross profit of €178.3 million and a gross profit margin of 58.15%. Operating expenses amounted to €51.0 million, contributing to a net income of €131.6 million and a net income margin of 42.92%.
PE: 11.7x
Sirius Real Estate, a European investment opportunity, has been actively expanding its portfolio with strategic acquisitions like Chalcroft Business Park in Southampton and Earl Mill in Oldham. These moves are funded by a €350 million bond issuance, indicating strong investor confidence. The company's recent insider confidence is reflected through board changes and leadership appointments to drive growth in the U.K. and Germany. With assets generating significant income and development potential, Sirius's small-cap nature offers appealing prospects amidst its financial strategies for long-term value creation.
Overview: Biotage is a company focused on providing solutions in the healthcare software sector, with operations contributing to its market capitalization of approximately SEK 11.67 billion.
Operations: The company generates revenue primarily from its healthcare software segment, with recent figures reaching SEK 2.06 billion. The gross profit margin has shown a notable upward trend, peaking at 62.73% in the latest period. Operating expenses are mainly driven by sales and marketing efforts and research and development activities, which have consistently been significant components of the cost structure.
PE: 27.7x
Biotage, a growing player in the European market, has caught attention due to insider confidence. Peter von Ehrenheim's significant purchase of 410,000 shares for SEK 47 million signals strong belief in its potential. Despite a dip in Q4 sales to SEK 582 million from SEK 643 million last year, net income rose to SEK 159 million. The company plans a dividend increase to SEK 1.65 per share for shareholders' approval. Earnings are projected to grow annually by over 20%, although reliance on external borrowing presents funding risks.
Overview: Nyab operates in the heavy construction industry with a focus on large-scale infrastructure projects, and it has a market capitalization of €1.25 billion.
Operations: The company generates revenue primarily from heavy construction, with recent figures showing €345.94 million. Over the observed periods, gross profit margins have fluctuated, reaching 24.40% in 2023-09-30 and 22.27% in 2023-12-31. Operating expenses are a significant cost component, including general and administrative expenses which were €39.26 million by the end of 2024-12-31. The net income margin was recorded at 4.84% for both the end of 2024 and early 2025 periods.
PE: 21.5x
Nyab, a small European company, is gaining attention due to its recent financial performance and strategic contracts. With sales rising to €345.94 million in 2024 from €280.42 million the previous year and net income nearly doubling, the company demonstrates potential for growth. Recent insider confidence is reflected in share purchases over the past months, signaling faith in future prospects. Key projects like the SEK 144 million North Bothnia Line contract further bolster Nyab's position within infrastructure development across Sweden.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LSE:SRE OM:BIOT and OM:NYAB.
